Business Context and Reporting Period
This Form 8-K Current Report, filed on February 25, 2025, by LifeStance Health Group, Inc. (LFST), announces significant executive leadership transitions effective in March 2025. The filing details the promotion of the current CFO to CEO, the retirement of the current CEO to Executive Chairman, and the appointment of a new CFO.
Key Financial Metrics
The filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and employment terms.
Material Changes and Leadership Transitions
- CEO Transition: David Bourdon, current CFO and Treasurer, is promoted to Chief Executive Officer effective March 3, 2025. He will also join the Board of Directors as a Class II director.
- Retirement: Kenneth Burdick, current CEO, is retiring effective March 3, 2025, and will transition to the role of Executive Chairman.
- New CFO: Ryan McGroarty is appointed as Chief Financial Officer and Treasurer, effective March 17, 2025, succeeding Mr. Bourdon.
Compensation and Management Commentary
The filing outlines specific compensation packages for the leadership changes:
- David Bourdon (CEO): Annual base salary of $700,000 with a target annual bonus of 100% of base salary for 2025 (blended).
- Kenneth Burdick (Executive Chairman): Annual base salary of $200,000 with a target annual bonus of 100% of base salary for 2025 (blended).
- Ryan McGroarty (CFO): Annual base salary of $550,000 with a target annual bonus of 85% of base salary starting in 2025. He will receive a one-time cash signing bonus of $570,000 and an initial equity award with a target grant date value of approximately $5,000,000 (split between time-based and performance-based RSUs).
- Severance: Mr. McGroarty's agreement includes 12 months of base salary continuation if terminated without cause or if he resigns for good reason.
Investor Verification Checklist
- Verify the exact effective dates of the leadership transitions (March 3, 2025, for CEO/Chairman; March 17, 2025, for CFO).
- Review the full text of the employment agreements (Exhibits to the upcoming Q1 2025 Form 10-Q) for detailed performance metrics tied to bonuses and equity vesting.
- Confirm the total equity grant value and vesting schedule for the new CFO, Ryan McGroarty.
- Monitor the upcoming press release (Exhibit 99.1) for additional strategic context regarding the leadership change.